 The following year, on November 2, 1999, Mary Schweitzer, a chronic fatigue syndrome patient who had been treated with rintatolimod, raised the question of why Ampligen has never been fast-tracked by the US public health authorities at the Chronic Fatigue Syndrome Co-ordinating Committee of the U.S. Department of Health and Human Services.Grassroots activism for FDA approval of Ampligen grew and continues.Current efforts in 2015 to spur FDA approval of Ampligen include petitions, appeal for congressional hearing, and popular social media group organizing.